Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
Open Access
- 19 April 2022
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (4) , e227958
Abstract
The US Food and Drug Administration (FDA) approves a new prescription drug if its benefits are judged to outweigh its risks in pivotal clinical trials1; the FDA and manufacturers then define the approved indications for the drug based on evidence from the trials. The indication is registered in drug labeling to guide prescribing and promotional statements. It can also help establish the contours of insurance coverage.2 However, pivotal trials leading to FDA approval are necessarily limited in the populations they cover.3 Although attention has been given to limitations in the demographic diversity of the trial population,4,5 less attention has been paid to whether a narrowly defined clinical trial population is then used as the basis for extrapolation of trial findings to a broader population of patients than was represented in those trials. Controversially, the FDA initially approved aducanumab in 2021 for all patients with Alzheimer disease, even though it was studied only in those with mild disease.6Keywords
This publication has 20 references indexed in Scilit:
- Histologic Classification of Non-Small-Cell Lung Cancer over Time: Reducing the Rates of Not-Otherwise-SpecifiedCurrent Oncology, 2015
- Clinical stratification of subtypes of Alzheimer's diseaseThe Lancet Neurology, 2012
- New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistanceCancer Treatment Reviews, 2012
- Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug ApplicationsThe Journal of Clinical Psychiatry, 2011
- Histology Matters: Individualizing Treatment in Non-Small Cell Lung CancerThe Oncologist, 2010
- The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practiceAnnals of the Rheumatic Diseases, 2007
- Generalizing results of randomized trials to clinical practice: reliability and cautionsClinical Trials, 2006
- Reimbursement for Cancer Treatment: Coverage of Off-Label Drug IndicationsJournal of Clinical Oncology, 2006
- Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation StudyNew England Journal of Medicine, 2004
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999